Illinois-based Abbott (NYSE:ABT) released a 2nd-quarter earnings report showing some strong momentum, but the healthcare giant’s medical device sector didn’t fare so well.
High-risk patients with mitral regurgitation reduced their symptoms and reported better quality of life after treatment with Abbott’s (NYSE:ABT) MitraClip implant, according to newly published results from the Everest II High Risk Registry.